A novel BRCA1 gene deletion detection in human breast carcinoma MCF-7 cells through FRET between quantum dots and silver nanoclusters

Publication date: 15 April 2018 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 152 Author(s): Yasaman-Sadat Borghei, Morteza Hosseini, Mohammad Reza Ganjali, Saman Hosseinkhani BRCA1 (breast cancer 1) genomic deletions are the most important founder mutations in breast cancer patients and can be passed to you from your mother or father. Herein, we report a silver nanoclusters-based (AgNCs-based) fluorescence resonance energy transfer (FRET) method for detection of BRCA1 gene deletion. The method relies on the specific hybridization of DNA-AgNCs fluorescent probe to deleted genes and interaction between double stranded DNA-AgNCs and QD, and the signal amplification through energy transfer from fluorescent AgNCs to QDs during FRET. Such fabricated QDs/DNA-AgNCs interaction might be beneficial for the nanomaterials based biosensing methods Under best possible conditions a linear correlation was established between the fluorescence intensity and the concentration of deletion sequence in the range of 5.0 × 10−13–1.0 × 10−9 M with a detection limit of 1.2 × 10−13 M. Using this method, we could effectively determine gene deletions by using the nonamplified genomic DNAs that were extracted from the MCF-7 as a breast cancer cell line.
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research

Related Links:

AbstractX chromosome gain has been previously described in male breast cancer (MBC). Androgen receptor (AR) gene is located on X chromosome. The aim of this study was to investigate the role of the X chromosome gain in the development of MBC and its relation with AR gene copy number and expression.The X chromosome status was assessed in 66 cases of male invasive and in situ duct breast carcinoma, in 34 cases of gynecomastia associated with cancer, and in 11 cases of tumor-free gynecomastia. Cases were tested by fluorescence in situ hybridization (FISH) to assess the X chromosome status and AR amplification. AR expression w...
Source: Virchows Archiv - Category: Pathology Source Type: research
CONCLUSIONS: The present study showed a deficiency in tamoxifen metabolism, characterized by intermediate metabolism in 8% of Brazilian women. PMID: 29787014 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
Conclusions Our meta-analysis suggested that patients with high primary SUVmax may experience a higher risk for recurrence or a poor progression. Moreover, the SUVmax of 18F-FDG showed a significant prognostic value in IDC patients.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Abstract The most significant contribution of molecular subtyping of breast carcinomas has been the identification of estrogen-positive and estrogen-negative tumor subtypes. Knowledge of genetic alterations in these tumors will help clinicians identify novel therapeutic targets. Understanding the progression pathways involved in the transition of in situ carcinoma to invasive carcinoma might lead to efficient risk stratification in these patients. The Cancer Genome Analysis Network has collected genomic and epigenomic data to provide comprehensive information regarding carcinogenesis and pathway interactions....
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Lab Med Source Type: research
ConclusionsOur data support results from recent phase I clinical trials using combinations of AZD2014 and PTX for the treatment of solid tumors. Such combinations may also be employed for the design of novel targeted ATC treatment strategies.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
Activation of the transcription factor estrogen receptor α (ERα) and the subsequent regulation of estrogen-responsive genes play a crucial role in the development and progression of the majority of breast cancers. One gene target of ERα, growth regulation by estrogen in breast cancer 1 (GREB1), is associated with proliferation and regulation of ERα activity in estrogen-responsive breast cancer cells. The GREB1 gene encodes three distinct isoforms: GREB1a, GREB1b and GREB1c, whose molecular functions are largely unknown. Here, we investigate the role of these isoforms in regulation of ERα activ...
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Research Source Type: research
AbstractObjectiveTo examine the effect of the aqueous extract ofLigustrum robustum on tumor growthin vitro andin vivo and explore the possible molecular mechanisms.MethodsInin vitro study, cell viabilities of human cervical carcinoma cells (HeLa), human breast cancer cells (MCF-7), human prostate cancer cells (PC-3), human hepatoma cells (7721) and human colon carcinoma cells (SW480) were evaluated with cell counting kit-8. ForL. robustum-treated Hela cells, early or late apoptosis were evaluated by annexin V/PI staining. Mitochondrial membrane potential was measured by staining cells with JC-1. Apoptosis was monitored by ...
Source: Chinese Journal of Integrative Medicine - Category: Internal Medicine Source Type: research
Conditions:   HER2-positive Breast Cancer;   Breast Cancer;   Breast Cancer Stage;   Recurrent Breast Cancer;   Metastatic Breast Cancer;   HER2 Positive Breast Carcinoma Interventions:   Drug: Palbociclib;   Drug: T-DM1 Sponsors:   University of Arizona;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In conclusion, our study reveals that down-regulation of KIF2A can inhibit gastric cancer cell invasion by suppressing MT1-MMP. This article is protected by copyright. All rights reserved. PMID: 29781531 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research
In conclusion, these results overall suggest that primary tumors showing sensitivity to continuous pazopanib treatment may predict response to this drug when given at high doses intermittently in the context of advanced metastatic disease, that are otherwise resistant to the conventional protocol.
Source: Angiogenesis - Category: Molecular Biology Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Genetics | Nanotechnology